Immuno-Oncology Cell Therapy Market to Reach $95.3 Billion by 2034, Fueled by CAR-T & TCR Therapies

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Immuno-Oncology Cell Therapy Market Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, Cytokine-induced killer cells, Dendritic cells, Macrophages, and Other Cell Therapies), Major Indication (Head & Neck Cancer, Lung Cancer, Kidney Cancer, Melanoma, Lymphoma, Leukemia, and Others) - Technology Trends, Clinical Trial/Pipeline Analysis, Revenue and Forecast Till 2034."

According to the latest market research research, the global Immuno-oncology cell therapies market size is valued at USD 11.9 Billion in 2024, and it is expected to reach USD 95.3 Billion by the year 2034 recording a promising CAGR of 23.2% from 2025 through 2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1083

The emergence of advanced immunotherapies has significantly transformed the landscape of oncology. As a progressive approach to cancer treatment, immunotherapy harnesses the body's immune system to detect, target, and eliminate malignant cells. Immuno-oncology, in particular, focuses on biologically enhancing the immune response to inhibit tumor progression. The development of next-generation immunotherapies is expected to further accelerate growth within the oncology sector over the forecast period, supported by a robust pipeline of clinical trials and recent regulatory approvals that validate their potential as both first-line and adjunct treatment options.

One of the most notable advancements in this domain has been the approval of chimeric antigen receptor T-cell (CAR-T) therapies. Ongoing research efforts are centered on broadening therapeutic indications, improving safety profiles, and refining manufacturing processes to increase scalability and efficiency. Furthermore, the COVID-19 pandemic has highlighted the importance of immune-based therapies, thereby accelerating demand and investment in immuno-oncology solutions.

Several factors are contributing to the expansion of the immuno-oncology cell therapy market. These include the rapid shift toward immunotherapeutics over traditional cancer treatments, advancements in bioinformatics, the high global cancer burden, and the increasing focus on personalized medicine. For instance, the American Cancer Society reported approximately 1.8 million new cancer cases and over 600,000 cancer-related deaths in the United States in 2020.

In response, heightened research activity and financial support from governmental health agencies and leading pharmaceutical companies are driving innovation in immuno-oncology. Additionally, the integration of sophisticated bioinformatics tools has improved efficiency in drug development by reducing associated costs and timelines, thereby enabling more effective evaluation of therapeutic candidates. These technological and scientific advancements are fostering continued research and adoption of novel cancer immunotherapies, further propelling market growth.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Despite the promising outlook, the growth of the immuno-oncology cell therapy market is expected to be tempered by several challenges. Chief among these are the high costs associated with therapy development and administration, rigorous regulatory requirements-particularly those related to biomarker validation-and insufficient reimbursement frameworks. These factors may hinder patient access and limit widespread adoption over the forecast period.

Geographically, North America is projected to retain its leading position in the market, supported by substantial healthcare expenditure, strong public awareness, and the presence of advanced medical infrastructure. Europe also commands a considerable share, driven by sustained government funding for research and development, as well as a high level of clinical trial activity within the region's healthcare landscape.

The Asia Pacific region is forecasted to witness the fastest growth through 2030, propelled by a rising incidence of cancer, increasing utilization of bioinformatics in drug development, and strengthened government investments in healthcare infrastructure. Key markets contributing to this regional expansion include China, India, and Japan.

The global immuno-oncology cell therapy market remains highly fragmented, with a large number of industry participants actively engaged in clinical development. Many therapeutic candidates currently in the pipeline are expected to secure regulatory approval in the near term. To consolidate their market positions, leading companies are implementing strategic initiatives such as product launches in established markets, geographic expansion, collaborative partnerships, licensing arrangements, and mergers and acquisitions.

For instance, in January 2021, Novartis (Switzerland) entered into a collaboration agreement with BeiGene, Ltd., granting Novartis rights to develop and commercialize tislelizumab outside of China. This agreement is aimed at strengthening Novartis's position within the expanding checkpoint inhibitor segment. Tislelizumab, an anti-PD-1 monoclonal antibody, has been specifically engineered to minimize its binding affinity to Fcγ receptors on macrophages, thereby potentially enhancing its therapeutic efficacy.

The global immuno-oncology cell therapy market covers prominent players like Agios Pharmaceutical, Atara Biotherapeutics, Novartis, Juno Therapeutics, Allogene Therapeutics, Shenzhen BinDeBio Ltd., Kite Pharma, Autolus Limited, China Immunotech Co., Ltd., Bellicum Pharmaceuticals, bluebird bio, CARsgen Therapeutics, Cell Design Labs, Calibr, Carina Biotech, Editas Medicine, Celgene Corporation, Cellectis, Cell Medica, Amgen, Celularity, Celyad, Fortress Bio, Fate Therapeutics, Gilead Sciences, JW Therapeutics, Mustang Bio, Ziopharm, Sorrento Therapeutics, Inc., Medigene, Medisix Therapeutics, Precision Biosciences, Lion TCR, Nanjing Legend Biotech, Posedia Therapeutics, Zelluna Immunotherapy, and others prominent players.

Key Developments:
• In Dec 2021, Novartis unveiled T-ChargeTM, its next-generation CAR-T platform, which will serve as the platform for several new investigational CAR-T cell therapies in the Novartis pipeline. Novartis continues to improve the T-Charge platform, which protects T cell stemness, a crucial attribute linked to therapeutic potential, while also implementing significant process savings.
• In Nov 2021, CARsgen Therapeutics Holdings Limited announced that CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer (GC/GEJ), has been granted Priority Medicines (PRIME) eligibility by the European Medicines Agency (EMA).
• In Aug 2021, The U.S. Food and Drug Administration (FDA) has approved Kite's Investigational New Drug (IND) application for KITE-363, the company's first chimeric antigen receptor (CAR) T-cell treatment that targets two antigens, CD19 and CD20. Kite intends to begin a multi-center Phase 1 clinical trial assessing KITE-363 in large B-cell lymphoma with this approval (LBCL).
• In Aug 2019, Celgene and Immatics Biotechnologies will collaborate to explore breakthrough adoptive cell therapies for a variety of diseases. Immatics plans to develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programmes targeting solid tumour targets found by Immatics' XPRESIDENT technology under the terms of the firms' strategic collaboration and option agreement.
• In Jan 2018, Celgene Corporation (U.S.) acquired Juno Therapeutics, Inc. (U.S.), a company engaged in the development of CAR T and TCR (T cell receptor) therapeutics. This acquisition added a novel scientific platform and scalable manufacturing capabilities to complement Celgene's haematology and oncology leadership.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1083

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Therapy Type
• CAR-T Cells
• N.K. & NKT Cells
• TAA/TSA targeted T Cell
• TCR T Cell
• Cytokine-induced killer cells
• Dendritic cells
• Macrophages
• Other Cell Therapies
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Major Indication
• Head & Neck Cancer
• Lung Cancer
• Kidney Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• Europe
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
Europe Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
North America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Asia Pacific Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• South Africa
• GCC Countries
• Rest of Middle East & Africa

Why should buy this report:
• To receive a detailed analysis of the prospects for global Immuno-oncology cell therapies market
• To receive clinical trial/pipeline analysis of Immuno-oncology cell therapies market
• To analyze the Immuno-oncology cell therapies market drivers and challenges
• To get information on Immuno-oncology cell therapies market size value (US$ Mn) forecast till 2030
• Mergers & Acquisition, Major Investments, in Immuno-oncology cell therapies market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-immuno-oncology-cell-therapy-market/1083

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.